Upcoming Earnings: Q2 '26
Estimated EPS
-$0.89
Estimated Rev
$21.98M
$RCUS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.02 up 10.53% YoY • Reported revenue of $17M down -39.29% YoY • Arcus Biosciences believes its $876M in cash, cash equivalents, and marketable securities as of March 31, 2026, will fund planned operations until at least the second half of 2028.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.89 | -- | -- | N/A |
Q1 '26 | -$0.88 | -$1.02 | -15.88% | MISSED |
Q4 '25 | -$1.11 | -$0.89 | 19.55% | BEAT |
Q3 '25 | -$1.31 | -$1.27 | 3.05% | BEAT |
Q2 '25 | -$1.13 | -$1.11 | 1.85% | BEAT |